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Objective: To investigate the relationship between the polymorphism of human leukocyte
antigen  (HLA)-DRB1 and the susceptibility and repellency of drug use combined with HIV
infection  in Chinese.
Methods:  A total of 213 unrelated healthy people, 41 HIV-infected drug users, 24 HIV-
uninfected  drug users, and 64 HIV-infected non-drug users were recruited. Their HLA-DRB1
allele  frequencies were analyzed by PCR-SSP and allele distribution was analyzed.
Results: Compared with healthy controls, in drug users, the frequencies of HLA-DRB1
*0401-041,  *1001 were signiﬁcantly higher; in HIV-infected patients, the frequencies of
HLA-DRB1 *0101-0103, *0401-0411, *1001 were signiﬁcantly higher, while the frequencies
of  DRB1 *1501-1502, *1101-1105, *1301-1302, DRB4, DRB5 were signiﬁcantly lower; in HIV-
infected  drug users, the frequencies of HLA-DRB1 *0101-0103, *0401-0411, *0801-0806, *1001,
*1401/1404/1405  were signiﬁcantly higher, while the frequencies of DRB1 *1301/1302, 1501-
1502,  DRB5 were signiﬁcantly lower.
Conclusion: There is close relationship between the polymorphism of HLA-DRB1 alleles anddrug  use with HIV infection, which plays an important role in elucidating the pathogenesis
and  providing the basis for therapeutics and prophylaxis of patients with drug use and HIV
infection.
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Este é um artigo Open Access sob a licença de CC BY-NC-NDDrug abuse is a serious social problem. By October 2011,
recorded drug users in China has reached 1.7 million, of
which  the number of the death due directly to drug abuse is
50,000.  Actual death toll may  be even higher. Many complica-
tions  accompany with drug users, of which HIV infection is
the  most common. Individuals show signiﬁcant difference in
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Este é um artigo Open Acdrug use combined with HIV infection, which mainly depends
on  human major histocompatibility complex (MHC). Human
leukocyte  antigen (HLA), the gene product of MHC, is a geneticf Virology, School of Medicine, Wuhan University, Wuhan 430071,
system  which is ﬁrst discovered related to disease. As an
important  gene cluster related to immune system function in
humans, different genotypes of HLA complex may  inﬂuence
cess sob a licença de CC BY-NC-ND
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he susceptivity and repellency of drug use combined with
IV  infection. HLA complex, a group of closely linked gene
luster,  exists in short arm of the human sixth chromosome.
he  codogenic HLA antigen determines the reject reaction of
rganism,  and is related to immune response and immuno-
ogical  regulation. HLA complex is divided into HLA-I, HLA-II
nd  HLA-III according to different gene product and gene func-
ion,  and is coded as antigen HLA-I, antigen HLA-II and antigen
LA-II.  Class II gene is named as HLA-D, which can classiﬁed
nto  HLA-DR, HLA-DQ, HL-DP and other subregions, mainly
xpressed in immunocell. They can be functioned as labeled
olecules  among immunocells to activate immune response
nd  regulate the interaction of immunocells, and plays an
mportant  role in immune response.4–7 For the high polymor-
hism  of HLA complex, same phenotype in every individual
s  very rare, thus HLA becomes an important target in the
nvestigation of many  diseases, including autoimmune dis-
ase,  infectious diseases, tumor and so on.8–12 High expression
f  HLA-DR is a symbol of T cell activation. According to statis-
ics  made by International Histocompatibility Working Group
IHWG),  the number of alleles among noetic DRB1 sites in anti-
ens  HLA-II was  494, and this polymorphism was  the main
enetic  factor13,14 to induce immune response in different
ndividuals and different susceptivity to disease among the
Table 1 – HLA-DRB1 allele-speciﬁc primers.
5′-Primers Sequence
5′ → 3′
3′-Primers 
5′01 TTGTGGCAGCTTAAGTTTGAAT 3′047 CTG
3′048 CTG
5′01 TTGTGGCAGCTTAAGTTTGAAT 3′10 CCC
5′02 TCCTGTGGCAGCCTAAGAG 3′01 CCG
5′02 TCCTGTGGCAGCCTAAGAG 3′02 AGG
5′03 TACTTCCATAACCAGGAGGAGA 3′03 TGC
5′06 GACGGAGCGGGTGCGGTA 3′048 CTG
5′03 TACTTCCATAACCAGGAGGAGA 3′047 CTG
5′04 GTTTCTTGGAGCAGGTTAAACA 3′048 CTG
3′047 CTG
5′07 CCTGTGGCAGGGTAAGTATA 3′079 CCC
5′08 ACTACTCTACGGGTGAGTGTT 3′05 CTG
5′09 GTTTCTTGAAGCAGGATAAGTTT 3′079 CCC
5′10 CGGTTGCTGGAAAGACGCG 3′047 CTG
5′05 GTTTCTTGGAGTACTCTACGTC 3′06 CTG
5′08 ACTACTCTACGGGTGAGTGTT 3′08 CAC
5′03 TACTTCCATAACCAGGAGGAGA 3′10 CCC
5′05 GTTTCTTGGAGTACTCTACGTC 3′045 TGT
5′03 TACTTCCATAACCAGGAGGAGA 3′17 CCC
5′05 GTTTCTTGGAGTACTCTACGTC 3′11 TCT
5′08 ACTACTCTACGGGTGAGTGTT 
5′03 TACTTCCATAACCAGGAGGAGA 3′12 GTA
5′04 GTTTCTTGGAGCAGGTTAAACA 3′19 CTG
5′52.1 TTTATTGGAGGCTGCGTAAGTC 3′13 CTG
5′52.2 GTTTCTTGGAGCTGCTTAAGTC 3′14 GCT
5′53 GAGCGAGTGTGGAACCTGA 3′048 CTG
5′51 GTTTCTTGCAGCCAGGATAAGTA 3′01 CCG
3′16 CCG
TGCCAAGTGGAGCACCCAA GCA 1 4;1  8(1):82–87  83
group. In the study, polymerase chain reaction-sequence spe-
ciﬁc  primers (PCR-SSP) was  used to test HLA-DRB1 genotype
among  41 HIV-infected drug users, 24 HIV-uninfected drug
users,  and 64 HIV-infected non-drug users, and compared with
HLA-DRB1  genotype of 213 healthy people, to explore the rela-
tionship  between gene polymorphism of HLA-DRB1 and drug
use  combined with HIV infection.
In the pilot study, 41 HIV-positive drug users (average age
37  ± 16), including 27 males and 14 females recruited from
Centre  for Disease Control and Prevention (Hubei, China) and
Dali  Drug Rehabilitation Center (Yunnan, China), were  con-
ﬁrmed  as HIV infectors by Western blot. 24 HIV-uninfected
drug users (average age 30 ± 11), including 12 males and 12
females,  were recruited from Dali Drug Rehabilitation Center
(Yunnan,  China). 64 HIV-positive non-drug users (average age
42 ± 9), including 44 males and 20 females, were  recruited from
Wuhan,  Qichun, Songzi, Huangshi and nearly ten countries
and  cities by Centre for Disease Control and Prevention (Hubei,
China),  and were conﬁrmed as HIV infectors by Western blot.
213  healthy people (average age 39 ± 11), including 138 males
and  75 females, were  healthy people or healthy blood donors
who  had no blood relationship and were selected randomly
from  Zhongnan Hospital of Wuhan University, Wuhan Cen-
tral  Blood Bank, Wuhan Third Hospital, and Tongji Hospital
Sequence
5′ → 3′
Size of PCR
product (bp)
DRB  primer
ampliﬁed
speciﬁcity
CACTGTGAAGCTCTCAC 255 0101-0102
CACTGTTGAAGCTCTCCA 255
GCTCGTCTTCCAGGAT 130 0103
CGCCTGCTCCAGGAT 197 1501-1502
TGTCCACCGCGGCG 213 1601-1602
AGTAGTTGTCCACCCG 151 0301-0302
CACTGTGAAGCTCTCCA 217 0301
CACTGTGAAGCTCTCAC 189 0302, 1302, 1305,
1402,  1403, 1409
CACTGTGAAGCTCTCCA 260 0401-0411
CACTGTGAAGCTCTCAC 260
GTAGTTGTGTCTGCACAC 232 0701-0702
CAGTAGGTCTCCACCAG 214 0801-0806
GTAGTTGTGTCTGCACAC 236 0901
CACTGTGAAGCTCTCAC 204 1001
GCTGTTCCAGTACTCCT 176 1101-1105
TGTGAAGCTCTCCACAG 248 1201-12-2
GCTCGTCTTCCAGGAT 130 1301-1302
TCCAGTACTCGGCGCT 171 1303-1305
GCCTGFACTTCCAGGAA 200 1305
GCAATAGGTGTCACACT 224 1401, 1404, 1405
1407, 1408
GGTGTCCACCGCGGCCCG 146 1402, 1404, 1305,
1306,  1409
TTCCAGTCTCCGCGA 188 1410
TTCCAGGACTCGGCGA 171 DRB3
GTTCCAGTAACTCGGCAT 173 0101-0301
CACTGTGAAGCTCTCCA 213 DRB4
0101
CGCCTGCTCCAGGAT 198 DRB5
CGGCGGCCTGTC 207 0101-0202
TCTTGCTCTGTGCAGAT 796 Human growth
hormone
84  b r a z j i n f e c t d i s . 2
Table 2 – HLA-DRB1 allele-speciﬁc of PCR/SSP
ampliﬁcation production.
Portion (lane) HLA DRB1 allele Primer
1 0101-0102 5′01 + 3′047 + 3′048
2  0103 5′01 + 3′10
3 1501-1502 5′02 + 3′01
4 1601-1602 5′02 + 3′02
5 0301-0302 5′03 + 3′03
6 0301 5′06 + 3′048
7 0302-1302-1305 5′03 + 3′047
1402-1403-1409
8 0401-0414-1401 5′04 + 3′047 + 3′048
9  0701-0702 5′07 + 3′079
10 0809-0806 5′08 + 3′05
11 0901 5′09 + 3′079
12 1001 5′10 + 3′047
13 1101-1105 5′05 + 3′06
14 1201-1202 5′08 + 3′08
15 1301-1302-1306 5′03 + 3′10
16 1303-1304-1305 5′05 + 3′045
17 1305 5′03 + 3′17
18 1401-1404-1405 5′05 + 5′08 + 3′11
1407-1408
19  1402-1305-1306 5′03 + 3′12
20 1410 5′04 + 3′19
21 DRB3 5′52.1 + 5′52.2 + 3′13 + 3′14
0101-0301
22 DRB4 0101 5′53 + 3′048
23 DRB5 0101-0201 5′51 + 3′01 + 3′16
of Huazhong University of Science and Technology. 5 mL  of
anticoagulated blood was  collected respectively, and stored at
4 ◦C.
HLA-DRB1 allele sequence speciﬁc primers were  designed
based  on the reference sequences from GenBank database,
and  were  synthesized by Shanghai Sangon Biological Engi-
neering  Technology And Services Co., Ltd. (Tables 1 and 2).
Conventional  proteinase K-phenol-chloroform method
was  applied to extract genome DNA from peripheral blood
lymphocyte (PBL). The DNA concentration was determined
by  UV spectrophotometer and adjusted to 100 ng/L subse-
quently.
Every  PCR reaction tube contains 60 ng genomic DNA to be
tested,  0.5 U Taq polymerase, 200 mol  of dNTP, 2 pmol SSP of
each  HLA-DRB1 alleles. Conditions for PCR: denaturation at
94 ◦C for 5.5 min; renaturation at 55 ◦C for 40 s; elongation at
72 ◦C for 1 min, 30 cycles. In the last cycle, the elongation step
was  extended to 2 min  at 72 ◦C. PCR product was  analyzed
by  2% agarose gel (ethidium bromide was  contained) elec-
trophoresis (10–15 V/cm gel, 20 min). Bromchlorophenol blue
was  used as an indicator. DNA band appeared obviously under
UV.  1–20 pairs of primers were  DRB1 allele-speciﬁc or group-
speciﬁc,  respectively. 21–23 pairs of primers were HLA-DRB3,
-DRB4, DRB5 gene-speciﬁc, and they were  related to different
DRB1  alleles, respectively. Human growth hormone (796 bp)
was used as positive control of PCR ampliﬁcation, and the
assessment of PCR results referred to references.15
Direct counting method was  used to calculate allele GF.
Hardy-Weinberg equilibrium test was  used to analyze sam-
ples,  and relative risk (RR) was  calculated compared with
control  group. The formula: gene frequency (GF) = detected
number of people with HLA-DRB1 alleles/total number of 0 1 4;1  8(1):82–87
people  in each experimental group; RR = a × d/b × c, where a
and  b represent number of patients with positive (+) HLA-DRB1
alleles,  and number of patients with negative (−) HLA-DRB1
alleles in the same group, respectively; c and d represent num-
ber  of healthy people with positive (+) HLA-DRB1 alleles, and
number  of healthy people with negative (−) HLA-DRB1 alleles
in  the same group, respectively.
The  results of PCR products of each HLA-DRB1 allele are
shown  in Fig. 1. The distribution of HLA-DRB1 alleles and
RR  was analyzed. According to Table 3, in drug use patients
compared with healthy controls, the frequencies of *0401-041
(p  < 0.05, RR = 9.22), *1001 (p < 0.05, RR = 19.27) were  signiﬁ-
cantly higher; in HIV-infected patients compared with healthy
controls,  the frequencies of HLA-DRB1 *0101-0103 (Pc < 0.01,
RR  = 6.42), *0401-0411 (Pc < 0.01, RR = 21.93), *1001 (Pc < 0.05,
RR  = 10.43) were  signiﬁcantly higher, indicating the relation-
ship  with HIV susceptivity, while the frequencies of DRB1
*1501-1502 (Pc < 0.01, RR = 0.06), *1101-1105 (Pc < 0.01, RR = 0.16),
*1301-1302  (Pc < 0.01, RR = 0.10), DRB4 (Pc < 0.01, RR = 0.11),
DRB5  (Pc < 0.01, RR = 0.10) were signiﬁcantly lower than that in
healthy controls, indicating the relationship with HIV repel-
lency;  in HIV-infected drug users compared with healthy
controls, the frequencies of HLA-DRB1 *0101-0103 (p < 0.01,
RR  = 7.26), *0401-0411 (p < 0.01, RR = 16.73), *0801-0806 (p < 0.01,
RR  = 5.49), *1001 (p < 0.05, RR = 22.91). *1401/1404/1405 (p < 0.05,
RR  = 5.41) were  signiﬁcantly higher, while the frequencies of
DRB1  *1301/1302 (p < 0.01, RR = 0.600649), 1501-1502 (p < 0.01,
RR  = 0.18), DRB5 (p < 0.01, RR = 0.40) were  signiﬁcantly lower.
This  study showed that in HIV-infected group and HIV-infected
drug  use group, the number of alleles whose frequency
changed signiﬁcantly was  signiﬁcantly higher than that in
drug  use group, indicating that variability of drug use com-
bined  with HIV infection among different individuals is closely
related  with HLA-DRB1 gene polymorphism.
Drug users become one of the major sources responsible
for HIV transmission in China. According to “China HIV Pre-
vention  and Protection Report (2011)”, by the end of October
2011,  the estimated number of HIV patients in China is 78,000.
Among  these patients, 40% of them were  infected from needle
injection.  According to sentinel surveillance data, 7% of nee-
dle  injection drug users obtained a positive outcome for HIV
test  in recent years. Once HIV-1 intrudes into human body,
virus  will integrate with cells and can barely be removed in
their  lifetime. Since viral genes can change into various types,
viral  genome is far more  complicated than any of a recog-
nized  virus. Therefore, HIV-1 infection has become a serious
threat  to human health. Two reasons lead to the wide dissem-
ination  of HIV in drug users1: high-risk drug use behaviors.
Generally, sharing injectors is considered to be the main rea-
son  for HIV infection2; unsafe/commercial sexual behavior of
drug  users was another reason contributing to the popularity
of  AIDS among drug users. In addition, some studies showed
that  except for drug dependence and virus, different immune
reactions  among different individuals was important in the
development  of disease among drug use combined with HIV
infectors.  HLA has a close relationship with human immune
functional status, and 39.8% genes of the 128 HLA functional
genes  are related to immunity.15 Especially, almost every gene
in  class II shows related functions to immunity. Among them,
HLA-DRB1  (contains 494 alleles) polymorphism is the most
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Table 3 – Distribution of HLA-DRB1 alleles in each experimental group.
DRB alleles Control
group
Drug user
group
HIV infected
group
Drug  user with
HIV infection
group
Comparison between
Drug user group and
Control group
Comparison between
HIV infected group and
Control group
Comparison  between Drug
user  with HIV infection
group  and Control group
Noa Rate Noa Rate Noa Rate Noa Rate X21 Pc1 RR1 X
2
2 Pc2 RR2 X
2
3 Pc3 RR3
DRB1
0101-0103 4 0.019 1 0.042 7 0.109 5 0.122 0.547 p > 0.05 2.27 8.35 p < 0.01 6.42 10.708 p < 0.01 7.26
0401-0411 1 0.004 1  0.042 6 0.094 3 0.073 3.524 p < 0.05 9.22 12.44 p < 0.01 21.93 10.400 p < 0.01 16.73
0809-0806 9 0.042 2  0.0833 4 0.063 8 0.195 0.822 p > 0.05 2.06 0.451 p > 0.05 1.51 12.866 p < 0.01 5.49
1001 1 0.004 2 0.0833 3 0.047 4 0.098 10.278 p < 0.01 19.27 3.545 p < 0.05 10.43 15.365 p < 0.01 22.91
1401/1404/1405 2 0.009 1 0.0417 1 0.016 2 0.048 1.798 p > 0.05 4.59 0.179 p > 0.05 1.67 3.442 p < 0.05 5.41
1501-1502 47 0.221 3 0.125 1 0.016 2 0.049 1.186 p > 0.05 1.19 14.441 p < 0.01 0.06 6.524 p < 0.01 0.18
DRB5 72 0.038 5 0.208 3 0.047 7 0.171 1.514 p > 0.05 0.52 21.129 p < 0.01 0.10 4.491 p < 0.01 0.40
1601-1602 8 0.038 2 0.083 2 0.031 2 0.049 1.12 p > 0.05 2.33 0.056 p > 0.05 0.83 0.114 p > 0.05 1.31
0301- 18 0.085 2  0.083 5 0.078 4 0.098 0.00385 p > 0.05 0.985 0.026 p > 0.05 0.92 0.0741 p > 0.05 1.17
0302- 6 0.028 2 0.083 2 0.031 1 0.024 2.01 p > 0.05 3.14 0.017 p > 0.05 1.11 0.0183 p > 0.05 0.86
0302-, 1302- 17 0.080 4  0.17 3 0.047 3 0.073 2.01 p > 0.05 3.14 0.797 p > 0.05 0.57 0.0209 p > 0.05 0.91
0701-0702 10 0.047 3 0.125 6 0.094 3 0.073 2.53 p > 0.05 2.9 1.981 p > 0.05 2.10 0.487 p > 0.05 1.60
0901 29 0.14 2 0.083 11 0.721 6 0.15 0.529 p > 0.05 0.577 0.508 p > 0.05 1.32 0.0301 p > 0.05 1.09
1101-1105 36 0.17 2 0.083 2 0.031 5 0.12 0.233 p > 0.05 1.29 7.891 p < 0.01 0.16 0.563 p > 0.05 0.68
1201-1202 3 0.014 1 0.042 4 0.063 2 0.0488 0.989 p > 0.05 3.04 2.942 p > 0.05 4.67 2.14 p > 0.05 3.59
1301-1302 28 0.131 2 0.0833 1 0.016 1 0.0244 0.452 p > 0.05 0.601 7.047 p < 0.01 0.10 3.90 p < 0.05 0.17
1305- 7 0.033 2 0.0833 2 0.031 3 0.0731 1.503 p > 0.05 2.68 0.004 p > 0.05 0.95 1.48 p > 0.05 2.32
1402, 1404, 1409 12 0.056 3 0.125 3 0.047 5 0.122 1.715 p > 0.05 2.39 0.086 p > 0.05 0.82 2.37 p > 0.05 2.33
DRB3 25 0.117 5 0.208 5 0.078 4 0.0976 1.614 p > 0.05 1.98 0.785 p > 0.05 0.63 0.13 p > 0.05 0.81
DRB4 81 0.038 9 0.375 4 0.063 14 0.341 0.00255 p > 0.05 0.98 0.063 p < 0.01 23.366 0.22 p > 0.05 0.84
1410 2 0.09 1 0.042 1 0.016 1 0.0244 1.798 p > 0.05 4.59 0.179 p > 0.05 1.67 0.663 p > 0.05 2.63
1303-1304 25 0.117 1 0.042 3 0.047 2 0.0488 1.266 p > 0.05 0.33 2.692 p > 0.05 0.37 1.703 p > 0.05 0.39
a No, number of positive detected.
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Fig. 1 – PCR ampliﬁcation results of HLA-DRB1 Alleles. Positive bright band appeared in Lanes 3, 6, 8, representing the
allelotypes of HLA-DRB1 were  HLA-DRB1*1501-1502, 0301, 0401-0414-1401. And Lanes 21, 22, 23 represent DRB3, DRB4, and
DRB5, respectively. Each lane includes an internal PCR control amplicon of human growth hormone gene (about 800 bp
concordant with theoretical values).
complicated. This polymorphism is the main genetic factor
for  immune response in different individuals among the group
and  differences in susceptibility to disease.
To date, many  studies have showed the close relationship
between HLA-DRB1 gene polymorphism and infectious dis-
eases.  As a main gene cluster to regulate immune response,
HLA  complex is closely related with antiviral immune
response. Some special HLA genotypes may  have effect on
the  strength of the immune response after the viral infec-
tion,  thus leading to the persistent virus infection. You et al.
studied  alleles HLA-DRB1 *1301/1302, 1501/1502, 1201/1202 in
patients with hepatitis B using PCR-SSP technology, and drew
a  conclusion that allele GF of HLA-DRB1 *1301/1302 among
patients  with chronic hepatitis B was  0.56%, which was  sig-
niﬁcantly  lower than control group (p < 0.05); the other two
alleles  had no signiﬁcant difference (p > 0.05). Cheng et al.
found  that allele GF of HLA-DRB1 *1201/1202 was  signiﬁ-
cantly  higher than control group (p < 0.001, RR = 4.99) among
patients  with liver cirrhosis in Hubei province, while GF of
HLA-DRB1  *1501/1502 alleles was  signiﬁcantly lower (p < 0.005,
RR  = 0.30). Other researchers found that allele GF of HLA-DRB1
*1301/1302 among European chronic hepatitis B infectors was
5.7%,  which was  lower than healthy people (26.7%); they also
found  that allele GF of HLA-DRB1 *1301/1302 was  signiﬁcantly
higher  among patients with acute hepatitis B than that among
patients  with chronic hepatitis B.16–18 HLA-DRB1 gene poly-
morphism also has important research value in HIV infection.
MacDonald et al.19 found that in Africa Kenya population,
genotype of HLA-DRB1 *0102 was  a protective gene of HIV,
while  HLA-A *2301 is associated with a signiﬁcantly increased
risk  of HIV-1 infection. Among American white people, HLA-
DQB1  *0602 is related to susceptivity of HIV, while among
African-Americans, HLA-DQB1 *0605 is the allele which is
associated  with susceptivity. Moreover, American white peo-
ple with HLA-DQB1 *0603 shows certain degree of repellency,
but  African-Americans with HLA-DRB1 *04 shows repellency
20to  HIV infection.
Our ﬁndings showed that allele frequency of HLA-DRB1
*0101-0103, *0401-0411, *0801-0806, *1001, *1401/1404/1405 in
HIV-infected drug use group were  signiﬁcantly higher thanthat in control group (p < 0.01 or p < 0.05), indicating that they
may  be the predisposing genes of drug use combined with
HIV  infection, while allele frequency of HLA-DRB1 *1301/1302,
*1501-1502, DRB5 were signiﬁcantly lower than that in control
group,  indicating that they may  be the protecting genes. On the
contrary,  HLA-DRB1 *0101-0103, * 0401-0411, *1001 may  related
to  HIV susceptivity in HIV-infected group, while HLA-DRB1
*1501-1502, *1101-1105, *1301-1302, DRB4, DRB5 may  related
to  HIV repellency. Compared with control group, allele fre-
quency  of only HLA-DRB1 *0401-0411, *1001 were  signiﬁcantly
higher. Studies showed that different alleles have different
frequencies, thus leading to distinguished difference of sus-
ceptivity  and repellency to disease among different groups.
Only  two allele’s frequency changed signiﬁcantly in drug users
group,  but there were 3 susceptibility alleles and 5 resistance
alleles  in HIV-infected group; 5 susceptibility alleles and 3
resistance  alleles in drug user with HIV-infected group. These
studies  indicated the close relationship between HLA-DRB1
alleles  and HIV infection. Susceptivity or repellency of drug
use  combined with HIV is different in different races. Thus,
the  investigation of HLA-DRB1 alleles has certain clinical and
basic  effect on the susceptivity or repellency of drug use com-
bined  with HIV. The study on the relationship between HLA
and  drug use combined with HIV at DNA level will help for elu-
cidating  pathogenesis of diseases and mechanism of immune
response,  and meanwhile will help for ﬁnding new effective
target  in the treatment of drug use combined with HIV infec-
tion.
The  preliminary study is limited for the relatively small
number of patients studied. Further study will be studied
including more  patients, and also focused on clinicopathologic
parameters in a larger cohort of patients. Besides, the associ-
ation  of HLA-DRB1 alleles and susceptibility of HIV infection
will  be studied by comparing the HIV infected individuals
considering the drug use as variable in our further research.Conﬂicts  of  interest
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